Enveda, a biotech startup focused on AI-driven drug discovery from natural sources, has secured $311 million in a Series E funding round, bringing its valuation to $2 billion. This funding round was led by Catalio Capital Management, with participation from Iconiq and others, effectively doubling its valuation from a year ago.